The diagnostic accuracy of digital PCR, ARMS and NGS for detecting KRAS mutation in cell-free DNA of patients with colorectal cancer: A protocol for systematic review and meta-analysis
Introduction: Cetuximab and panitumumab has been used clinically to treat metastatic colorectal cancer for over 15 years. Before the treatment is given, it is necessary to determine the KRAS mutation status because it would lead to drug resistance. tumor tissue sample is traditionally used for genotyping of cancer. In recent years, the biopsy sample liquid has been intensively investigated as a substitute for tumor tissue samples for non-invasive and better presentation of tumor heterogeneity.
The purpose of this study was to systematically summarize the accuracy of the measurement of KRAS mutations in colorectal cancer using the cell-free DNA in the sample liquid biopsy, the tumor tissue samples as reference (gold standard). Methods and analysis: We will find literature in the following databases: Pubmed, Embase, and the Cochrane Library. systemic review and meta-analysis will be conducted to summarize the accuracy of the measurement of KRAS mutations in colorectal cancer using biopsy samples of liquid and subgroup analyzes will be performed on different testing platforms, and in colorectal cancer metastatic and non-metastatic. Timeline: The research will begin on June 1, 2020, and is expected to be completed date of 1 November 2020.
Ethics and deployment: Ethics approval will not be required because the data obtained and analyzed in this study will not be in each patient. The results of the research will be disseminated as an official publication in peer-reviewed
A PCR-based NGS protocol for whole genome sequencing of West Nile virus 2 direct descendant of biological specimens.
Lineage 2 West Nile virus (WNV) strain has been involved in a severe outbreak of encephalitis in humans and equines which are in Europe. WNV molecular characterization is important for the development of diagnostic tests, and to obtain molecular information, which is necessary for epidemiological investigations in areas at risk of virus transmission.
For whole-genome sequencing of strains of WNV lineage 2, directly from biological specimens, PCR-based NGS protocol developed. This method is applied to the WNV-positive specimens were obtained from animals, human and mosquito hosts in Greece. Outcomes of the application shows that, even in the case of a low viral titers, developed PCR-based NGS approach capable of providing whole genome sequence of strain lineage 2 WNV.
The diagnostic accuracy of digital PCR, ARMS and NGS for detecting KRAS mutation in cell-free DNA of patients with colorectal cancer: A protocol for systematic review and meta-analysis
The latest trends in molecular diagnostics yeast infection: PCR for NGS.
The incidence of opportunistic yeast infections in humans has increased in recent years. These infections are difficult to treat and diagnose, partly because the large number and wide variety of species that can be underlying infection.
Moreover, resistance to one or more of antifungal drugs in a strain that infects more and more reported, severely limiting therapeutic options and to show the need for rapid detection of infecting agents and the profile of its drug susceptibility.
Current methods for species identification of constraints and shortage of sensitivity and specificity were satisfactory, and often require a previous culture of the infecting agent, which delays diagnosis.
Recently developed high-throughput technologies such as next-generation sequencing or proteomics opens a completely new way to diagnose more sensitive, accurate and rapid pathogenic yeast. These approaches are the focus of intensive research, but the translation to the clinic needed to overcome important challenges. In this review, we provide an overview of existing approaches and recently appeared which can be used in the identification of the yeast pathogens and their drug resistance profile.
Description: A polyclonal antibody against CD79B. Recognizes CD79B from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:2000, IHC:1:50-1:200
Description: A polyclonal antibody against CD79B. Recognizes CD79B from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:2000, IHC:1:50-1:200
Description: A polyclonal antibody against CD79B. Recognizes CD79B from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IF; Recommended dilution: IF:1:50-1:200
Description: A polyclonal antibody against CD79B. Recognizes CD79B from Human. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/20000
Description: Recombinant fusion protein containing a sequence corresponding to amino acids 2645-2813 of human von Willebrand factor (VWF) (NP_000543.3).
Throughout the text we highlight the advantages and disadvantages of each methodology and discuss the most promising developments in their path from bench to bedside.
Kent
